GLP's Peptides
Research compounds in the GLP's category. Click any peptide for full profile details.
GLP's
FDA-approved melanocortin-4 receptor agonist for treating obesity caused by rare genetic disorders affecting the leptin-melanocortin pathway.
GLP's
FDA-approved synthetic amylin analog that complements insulin therapy by slowing gastric emptying, reducing glucagon, and enhancing satiety.
GLP's
Gut-derived satiety hormone that reduces appetite and regulates energy balance, with research implications for obesity treatment.
GLP's
FDA-approved GLP-1 receptor agonist for type 2 diabetes and cardiovascular risk reduction, administered once weekly.
GLP's
First GLP-1 receptor agonist approved for diabetes, derived from Gila monster venom, available in twice-daily and once-weekly formulations.
GLP's
FDA-approved short-acting GLP-1 receptor agonist with unique postprandial glucose control properties.
GLP's
Long-acting amylin analog that suppresses appetite and enhances satiety, being developed as a complement to GLP-1 drugs for…
GLP's
GLP-1/glucagon dual agonist designed for better body composition — promoting fat loss while preserving muscle mass during weight…
GLP's
Dual GLP-1/glucagon receptor agonist in Phase 3 trials showing potent weight loss and liver fat reduction.
GLP's
Fixed-dose combination of amylin analog cagrilintide with semaglutide for enhanced weight management research.